

# Severe or systemic autoimmune disease

This page was last modified on 18 May 2016, at 10:13.



## Contents

- [Condition](#)
- [Individual at risk](#)
- [Guidance at RECRUITMENT for adult volunteer donor and maternal donor \(cord blood donation\)](#)
- [Guidance at CT /WORK-UP](#)
- [Justification for guidance](#)
- [References](#)

## Condition

Severe or Systemic autoimmune disease, including:

Inflammatory bowel disease

Multiple sclerosis (MS)

Systemic lupus erythematosus (SLE)

Inflammatory arthritis (including rheumatoid arthritis)

Scleroderma/CREST

Sarcoidosis

Guillain-Barre syndrome

Wegener granulomatosis

Goodpasture syndrome

## Individual at risk

Donor / recipient

## Guidance at RECRUITMENT for adult volunteer donor and maternal donor (cord blood donation)

UNACCEPTABLE

## Guidance at CT/WORK-UP

QUALIFIED. Donors in remission of the above diseases who have not required systemic therapy for more than one year may be considered for donation on an individual basis, but should not receive granulocyte colony stimulating factor and thus donate by bone marrow only.

Risk of adoptive transfer of disease-causing cells should be discussed with the recipient, and risks of disease activation should be discussed with the donor.

## Justification for guidance

Autoimmune disease on this list can be passed by adoptive transfer of t-lymphocytes in experimental animal models, and these diseases are recapitulated in recipient animals. Donor genetic polymorphisms that predispose to inflammatory bowel disease may induce this disease in transplant recipients, and there is clinical evidence of disease transfer in donor:recipient pairs.

Donors with systemic autoimmune/inflammatory disease may be at risk for Macrophage Activation Syndrome upon administration of granulocyte colony stimulating factor.

## References

Anderlini P, Przepiorka D, Korbling M, Champlin R. Blood stem cell procurement: donor safety issues. *Bone Marrow Transplant* 1998; 21 Suppl 3: S35-9.

Bhagat R, Rizzieri DA, Vredenburgh JJ, Chao NJ, Folz RJ. Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence? *Chest* 2004; 126(2): 642-4.

Lampeter EF, Homberg M, Quabeck K, Schaefer UW, Wernet P, Bertrams J et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. *Lancet* 1993; 341(8855): 1243-4.

Lampeter EF, McCann SR, Kolb H. Transfer of diabetes type 1 by bone-marrow transplantation. *Lancet* 1998; 351(9102): 568-9.

Marmont AM. Autoimmunity and allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1992; 9(1): 1-3.

Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. *Neurology* 2000;54(11):2147-50.

Snowden JA, Atkinson K, Kearney P, Brooks P, Biggs JC. Allogeneic bone marrow transplantation from a donor with severe active rheumatoid arthritis not resulting in adoptive transfer of disease to recipient. *Bone Marrow Transplant* 1997; 20(1): 71-3.

Sonwalkar SA, James RM, Ahmad T, Zhang L, Verbeke CS, Barnard DL et al. Fulminant Crohn's colitis after allogeneic stem cell transplantation. *Gut* 2003; 52(10): 1518-21.

Vialettes B, Maraninchi D. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. *Lancet* 1993; 342(8864): 174.

Waters AH, Metcalfe P, Minchinton RM, Barrett AJ, James DC. Autoimmune thrombocytopenia acquired from allogeneic bone-marrow graft: compensated thrombocytopenia in bone marrow donor and recipient. *Lancet* 1983; 2(8364): 1430.